StockData
Sonoma Pharmaceuticals, Inc. logo

Sonoma Pharmaceuticals, Inc. (SNOA) stock

SNOANasdaqSurgical & Medical Instruments & ApparatusFiscal year ends March 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 11/3082% below fair value
$0.83−0.05 (-5.21%)

Close on Nov 17, 2026Market cap $3.99MP/E –Yield –

Sonoma Pharmaceuticals r&d expenses

Research and development expenses are spending on new products and technology.

Sonoma Pharmaceuticals's R&D Expenses for the twelve months ending Jun 30, 2026 was $2.27M, up 17.3% year over year. For fiscal 2026 it was $2.27M, up 25.2% from the year before. Over ten years it grew 2.3% a year on average. The highest annual figure on record is $2.89M in fiscal 2014.

Annual r&d expenses

PeriodPeriod endValueChange
FY2026Mar 31, 2026$2.27M+25.2%
FY2025Mar 31, 2025$1.81M-3.0%
FY2024Mar 31, 2024$1.87M+803.9%
FY2023Mar 31, 2023$207.00K+65.6%
FY2022Mar 31, 2022$125.00K-77.5%
FY2021Mar 31, 2021$555.00K-58.6%
FY2020Mar 31, 2020$1.34M-11.8%
FY2019Mar 31, 2019$1.52M-3.6%
FY2018Mar 31, 2018$1.58M-0.1%
FY2017Mar 31, 2017$1.58M-12.7%
FY2016Mar 31, 2016$1.81M+17.8%
FY2015Mar 31, 2015$1.53M-46.9%
FY2014Mar 31, 2014$2.89M+29.9%
FY2013Mar 31, 2013$2.22M+12.2%
FY2012Mar 31, 2012$1.98M-3.2%
FY2011Mar 31, 2011$2.05M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q1 FY2027CQ2 2026Jun 30, 2026$597.00K+0.5%
Q4 FY2026CQ1 2026Mar 31, 2026$545.00K+32.6%
Q3 FY2026CQ4 2025Dec 31, 2025$557.00K+30.4%
Q2 FY2026CQ3 2025Sep 30, 2025$575.00K+13.6%
Q1 FY2026CQ2 2025Jun 30, 2025$594.00K+26.4%
Q4 FY2025CQ1 2025Mar 31, 2025$411.00K+0.5%
Q3 FY2025CQ4 2024Dec 31, 2024$427.00K-29.0%
Q2 FY2025CQ3 2024Sep 30, 2024$506.00K-5.6%
Q1 FY2025CQ2 2024Jun 30, 2024$470.00K+44.6%
Q4 FY2024CQ1 2024Mar 31, 2024$409.00K+103.5%
Q3 FY2024CQ4 2023Dec 31, 2023$601.00K–
Q2 FY2024CQ3 2023Sep 30, 2023$536.00K+168.0%
Q1 FY2024CQ2 2023Jun 30, 2023$325.00K+57.8%
Q4 FY2023CQ1 2023Mar 31, 2023$201.00K+4925.0%
Q3 FY2023CQ4 2022Dec 31, 2022$0-100.0%
Q2 FY2023CQ3 2022Sep 30, 2022$200.00K+1900.0%
Q1 FY2023CQ2 2022Jun 30, 2022$206.00K+145.2%
Q4 FY2022CQ1 2022Mar 31, 2022$4.00K-96.9%
Q3 FY2022CQ4 2021Dec 31, 2021$26.00K-21.2%
Q2 FY2022CQ3 2021Sep 30, 2021$10.00K–
Q1 FY2022CQ2 2021Jun 30, 2021$84.00K-82.4%
Q4 FY2021CQ1 2021Mar 31, 2021$130.00K-73.1%
Q3 FY2021CQ4 2020Dec 31, 2020$33.00K-86.7%
Q2 FY2021CQ3 2020Sep 30, 2020-$85.00K-131.5%
Q1 FY2021CQ2 2020Jun 30, 2020$476.00K+40.8%
Q4 FY2020CQ1 2020Mar 31, 2020$483.00K+47.7%
Q3 FY2020CQ4 2019Dec 31, 2019$248.00K-45.0%
Q2 FY2020CQ3 2019Sep 30, 2019$270.00K-30.8%
Q1 FY2020CQ2 2019Jun 30, 2019$338.00K-3.4%
Q4 FY2019CQ1 2019Mar 31, 2019$327.00K-31.3%
Q3 FY2019CQ4 2018Dec 31, 2018$451.00K+29.2%
Q2 FY2019CQ3 2018Sep 30, 2018$390.00K+6.0%
Q1 FY2019CQ2 2018Jun 30, 2018$350.00K-8.4%
Q4 FY2018CQ1 2018Mar 31, 2018$476.00K+36.0%
Q3 FY2018CQ4 2017Dec 31, 2017$349.00K-28.3%
Q2 FY2018CQ3 2017Sep 30, 2017$368.00K-2.9%
Q1 FY2018CQ2 2017Jun 30, 2017$382.00K–
Q4 FY2017CQ1 2017Mar 31, 2017$350.00K–
Q3 FY2017CQ4 2016Dec 31, 2016$487.00K–
Q2 FY2017CQ3 2016Sep 30, 2016$379.00K–

More Sonoma Pharmaceuticals figures

See a number that looks wrong?